Mercer Paul F, Abbott-Banner Katharine, Adcock Ian M, Knowles Richard G
*Centre for Inflammation and Tissue Repair, Rayne Institute, University College London, London WC1E 6BT, U.K.
†Verona Pharma PLC, London SE1 1LB, U.K.
Clin Sci (Lond). 2015 Feb;128(4):235-56. doi: 10.1042/CS20140373.
The 2nd Cross Company Respiratory Symposium (CCRS), held in Horsham, U.K. in 2012, brought together representatives from across the pharmaceutical industry with expert academics, in the common interest of improving the design and translational predictiveness of in vivo models of respiratory disease. Organized by the respiratory representatives of the European Federation of Pharmaceutical Industries and Federations (EFPIA) group of companies involved in the EU-funded project (U-BIOPRED), the aim of the symposium was to identify state-of-the-art improvements in the utility and design of models of respiratory disease, with a view to improving their translational potential and reducing wasteful animal usage. The respiratory research and development community is responding to the challenge of improving translation in several ways: greater collaboration and open sharing of data, careful selection of the species, complexity and chronicity of the models, improved practices in preclinical research, continued refinement in models of respiratory diseases and their sub-types, greater understanding of the biology underlying human respiratory diseases and their sub-types, and finally greater use of human (and especially disease-relevant) cells, tissues and explants. The present review highlights these initiatives, combining lessons from the symposium and papers published in Clinical Science arising from the symposium, with critiques of the models currently used in the settings of asthma, idiopathic pulmonary fibrosis and COPD. The ultimate hope is that this will contribute to a more rational, efficient and sustainable development of a range of new treatments for respiratory diseases that continue to cause substantial morbidity and mortality across the world.
第二届跨公司呼吸研讨会（CCRS）于2012年在英国霍舍姆举行，来自整个制药行业的代表与专家学者齐聚一堂，共同致力于改善呼吸系统疾病体内模型的设计和转化预测性。该研讨会由参与欧盟资助项目（U-BIOPRED）的欧洲制药工业联合会（EFPIA）集团公司的呼吸领域代表组织，其目的是确定呼吸系统疾病模型在实用性和设计方面的最新改进，以提高其转化潜力并减少不必要的动物使用。呼吸研发界正在通过多种方式应对改善转化的挑战：加强合作与开放数据共享、谨慎选择模型的物种、复杂性和慢性程度、改进临床前研究实践、持续完善呼吸系统疾病及其亚型的模型、更深入了解人类呼吸系统疾病及其亚型的生物学基础，以及最后更多地使用人类（尤其是与疾病相关的）细胞、组织和外植体。本综述突出了这些举措，结合了研讨会的经验教训以及研讨会上发表在《临床科学》上的论文，并对目前用于哮喘、特发性肺纤维化和慢性阻塞性肺疾病（COPD）的模型进行了批评。最终的希望是，这将有助于更合理、高效和可持续地开发一系列新的呼吸系统疾病治疗方法，这些疾病在全球范围内仍导致大量发病和死亡。
